A Helminth-Derived Chitinase Structurally Similar to Mammalian Chitinase Displays Immunomodulatory Properties in Inflammatory Lung Disease

Immunomodulation of airway hyperreactivity by excretory-secretory (ES) products of the first larval stage (L1) of the gastrointestinal nematode Trichuris suis is reported by us and others. Here, we aimed to identify the proteins accounting for the modulatory effects of the T. suis L1 ES proteins and studied six selected T. suis L1 proteins for their immunomodulatory efficacy in a murine OVA-induced allergic airway disease model. In particular, an enzymatically active T. suis chitinase mediated amelioration of clinical signs of airway hyperreactivity, primarily associated with suppression of eosinophil recruitment into the lung, the associated chemokines, and increased numbers of RELMα+ interstitial lung macrophages. While there is no indication of T. suis chitinase directly interfering with dendritic cell activation or antigen presentation to CD4 T cells, treatment of allergic mice with the worm chitinase influenced the hosts' own chitinase activity in the inflamed lung. The three-dimensional structure of the T. suis chitinase as determined by high-resolution X-ray crystallography revealed high similarities to mouse acidic mammalian chitinase (AMCase) but a unique ability of T. suis chitinase to form dimers. Our data indicate that the structural similarities between the parasite and host chitinase contribute to the disease-ameliorating effect of the helminth-derived chitinase on allergic lung inflammation.


Introduction
Chronic helminth infections are known to be accompanied by various immunomodulatory processes. The active modulation of host immune responses is believed to ensure longterm persistence of the parasites and most likely involves proteins released by the worms (reviewed in [1][2][3]). Over the last decade, research has focused on identifying secreted helminth immunomodulators and mechanisms of suppression in order to understand natural infection and in parallel with the aim to exploit this knowledge for the benefit of unwanted human inflammatory diseases.
We and others have identified secreted products with immunosuppressive effects in autoimmune and inflammatory diseases from diverse parasitic helminths such as Acanthocheilonema viteae [4][5][6][7][8][9][10][11], Schistosoma [12][13][14][15], Fasciola hepatica [16,17], Heligmosomoides polygyrus [18,19], and Wuchereria bancrofti [20,21]. Among the organisms currently explored for helminth-induced therapy of humans are the pig whipworm (Trichuris suis, TSO), the human hookworm (Necator americanus, NC), and also the human whipworm (T. trichiura, TTO). As T. suis can be easily maintained in pigs but cannot multiply in humans, its administration as live parasite (TSO therapy) has been tested in a variety of clinical studies to improve human immune disorders (reviewed in [22]). Early success stories of treatments of ulcerative colitis (UC) and Crohn's disease (CD) with TSO [23][24][25] were followed by larger trials with only modest results for various autoimmune diseases [22,[26][27][28] and implicated the need for a greater understanding for the immunomodulatory mechanisms. In a rather small cohort of MS patients receiving controlled TSO treatment, we demonstrated varying degrees of parasite-specific T cell responses and cellular functionality across individuals receiving treatment, indicating the need to understand responders and nonresponders in order to develop more tailored treatment regimens [29].
T. suis has a direct life cycle. Upon ingestion of larval stage 1 (L1) containing infective eggs, the larvae hatch and invade the mucosa of the large intestine and develop into adults by molting several times [30]. When administered therapeutically to humans, there is evidence for a self-limiting, sterile colonization of T. suis [23]; thus, repeated TSO treatments are required. However, this transient exposure highlights the role of early larval stages to possess immunomodulatory properties. Using soluble products (Ts-SPs) or excretory-secretory proteins (Ts-ES) or isolated fractions from both adult worms and larval stages, several immunomodulatory mechanisms have been investigated [31][32][33][34]. Ts-SPs from adult worms have been shown to interfere with activation of human dendritic cells and macrophages [32,[35][36][37][38]. We have previously reported on the immunomodulatory activity of proteins collected from Ts L1 which interfere with CD4 + T cell priming and clinical parameters of experimental airway hyperreactivity [34]. Similarly, a recent study shows that Ts-ES proteins released by adult and larval stages of T. suis possess anti-inflammatory properties. Indeed, the authors identified a subset of proteins with anti-inflammatory properties within adult Ts-ES [31]. How-ever, immunoregulators of the very early larval stages of T. suis remain elusive.
Here, we focus on the identification and characterization of proteins selectively secreted by the first larval stages of T. suis. We screened a set of n = 6 recombinant larval proteins for immunomodulatory properties and identified an enzymatically active T. suis chitinase that interfered with recruitment of immune cells and inflammatory reactions in a murine model of allergic airway disease. While our in vitro data suggest no direct immunomodulatory effects on, e.g., DC function or T cell activation, we observed disease amelioration to be associated with suppression of eosinophil recruitment into the lung and increased numbers of alternatively activated RELMα + lung macrophages. X-ray crystallography revealed the structure of the nematode enzyme to be highly similar to the host's own chitinases. Since mammalian host chitinases, both true chitinases with enzymatic activity (AMCase and chitotriosidase) and chitinase-like protein (CLP) molecules which can bind to chitin but lack enzymatic activity, are implicated as either mediators or biomarkers involved in airway inflammation and fibrosis, disease amelioration by treating with a worm chitinase was rather surprising. Our findings further reveal that T. suis chitinase treatment of allergic mice not only inhibited host AMCase expression on mRNA level but also interfered with host chitinase activity in the BAL fluid, suggesting an alternative mechanism that might involve the high degree of structural similarity between host and nematode chitinases.

Ethics Statement.
Mice were cared for in accordance with the principles outlined in the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes and the German Animal Welfare Law. The mouse study was approved by the State Office of Health and Social Affairs Berlin, Germany (Landesamt für Gesundheit und Soziales; approval numbers G0144/10, T0407/17, and G0068/16).
The T. suis life cycle was maintained in pigs (Sus scrofa) in accordance with the principles outlined in the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes and the German Animal Welfare Law. The generation of larval material was approved by the State Office of Health and Social Affairs Berlin, Germany (Landesamt für Gesundheit und Soziales; approval number H0296/12).

Murine OVA-Induced Allergic Airway Disease.
Allergic airway inflammation was induced as previously described [4]. Briefly, female BALB/c mice (8 weeks old) were sensitized on days 0 and 14 with 20 μg ovalbumin protein (OVA, grade VI, Sigma-Aldrich Chemie GmbH, Munich, Germany) emulsified in 2 mg alum (Imject™ Alum, Ther-moFisher Scientific, IL, USA). Nonallergic control animals (PBS) received equal volumes of PBS on days 0 and 14 instead of OVA. Mice were treated with 20 μg recombinant, intact T. suis proteins or heat-inactivated proteins on days 0, 7, and 14 i.p. or left untreated. Intranasal OVA challenge (50 μg OVA/25 μl PBS) was performed on all groups of mice on days 28 and 29. Where indicated, lung function was assessed on day 30 at the Max Delbrück Center for Molecular Medicine (MDC) in Berlin. On day 31, mice were sacrificed, bronchoalveolar lavage (BAL) was performed, and samples were taken for analysis.
Data were sampled once per second. For data analysis, averages of 5 sec intervals were used. Airway resistance (S raw ) and expiratory time values were generated and analyzed using iox2 software (iox v2.8.0.13, emka Technologies). Resulting data points were averaged again per mouse and methacholine dose. Data points with success rate < 50% and beat number < 10 were excluded from the analysis.

Bronchoalveolar
Lavage. Intratracheal bronchoalveolar lavage (BAL) was performed on i.p. anaesthetized mice by inflating the lungs with 800 μl PBS containing protease inhibitor cocktail (cOmplete™, Mini, EDTA-free Protease Inhibitor, Roche Diagnostics GmbH, Mannheim, Germany). The 1 st BAL was pelleted, and the supernatant was stored at -20°C for cytokine/chemokine detection. Four additional lavages (4 × 800 μl PBS) were performed for cell isolation and pelleted by centrifugation. All cells were pooled in 500 μl PBS and counted using a Neubauer cell chamber. 2 × 100 μl cell suspension per sample was used for cytospin preparation. Object slides were dried and stained with Diff-Quick solutions (Labor und Technik Eberhard Lehmann GmbH, Berlin, Germany) for differential cell counts. Residual cells were used for flow cytometry.
2.6. Histology and Immunohistochemistry. Following lung lavage, the left lobe was split into two pieces. The lower tissue was degassed and fixed in a formalin solution (Roti-Histofix 10%, Carl Roth GmbH + Co. KG, Karlsruhe, Germany) for 6 h at room temperature and then stored at 4°C. The tissue was embedded in paraffin, and sections were stained with an antibody against RELM-α (polyclonal rabbit antimouse, Abcam, Cambridge, UK). Nuclei were stained with hematoxylin (Merck). Interstitial RELM-α + cells were quantified in 5 HPF (high-power fields, 400x magnification). Pictures are presented at 400x magnification. For evaluation of histomorphological changes, paraffin sections were stained with hematoxylin and eosin (H&E) and scored for inflammation and goblet cell hyperplasia. Briefly, score 1 is for minor perivascular inflammation, score 2 for moderate perivascular and peribronchial inflammation and minimal goblet cell hyperplasia, score 3 for increased perivascular and peribronchial inflammation and increased goblet cell hyperplasia (beginning in smaller airways), and score 4 for severe perivascular, peribronchial, and interstitial inflammation with goblet cell hyperplasia in smaller and larger airways.

T Cell Proliferation Assays
In Vitro. For studying effects of Ts-Chit on antigen-independent T cell proliferation, splenocytes were isolated from female BALB/c mice, labeled with CFSE in PBS (8 min, RT, 5 μM), and seeded at a density of 4 × 10 6 cells/ml in round-bottom 96-well plates. After 4 days of incubation (37°C, 5% CO 2 ) in the presence of plate-bound mouse αCD3/αCD28 (1 μg/ml) and recombinant Ts-Chit (10 μg/ml), DCs were harvested and analyzed for CFSE dilution in CD4 + and CD8 + T cells.
2.11. Quantitative RT-PCR. Following lung lavage, the upper right lobe was snap-frozen in liquid nitrogen and stored at -80°C. RNA isolation from lung tissues was performed using the innuPREP RNA Mini Kit (Analytic Jena AG, Jena, Germany) according to the manufacturer's instructions. Reverse transcription of 1 μg RNA into cDNA was done using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, CA, USA). RT-PCR was performed on the LightCycler® 480 instrument using the LightCycler® 480 SYBR Green I Master Mix (Roche Diagnostics, Mannheim, Germany) and oligonucleotides listed in Table 1. Gene expression is described relative to the housekeeping gene peptidylprolyl isomerase A (PPIA) and normalized to mRNA levels of the PBS group if not indicated differently.
T. suis L1 ES proteins were isolated from freshly hatched larvae as previously described [34]. Identification of T. suis larva ES proteins (in vitro-hatched L1, 10 dpi, 18 dpi, and 28 dpi) was done by mass spectrometry as previously described [34]. In brief, TCA-precipitated dried protein pellets of T. suis were suspended, reduced, alkylated, and tryptic digested. The resulting peptides were analyzed by LC-MSMS on a 4700 Proteomics Analyzer (ABSCIEX, Framingham, MS). Database searches were performed with Mascot software against NCBI database 20150331 (64057457 sequences). Proteins were accepted as identified if at least two MS/MS spectra provided a MASCOT score for identity (p < 0:01Þ. The genes corresponding to selected T. suis proteins were amplified and cloned into the vector pLEXSYsat2 of the Leishmania expression system (LEXSYcon2 Expression Kit, Jena Bioscience GmbH, Jena, Germany). The cloning vector was sequenced for verification. Leishmania tarentolae cells were transfected via electroporation (Nucleofector™ 2b Device, Amaxa™ Human T Cell Nucleofector™ Kit, Lonza, Basel, Switzerland) with the respective expression cassette containing the selective antibiotic marker nourseothricin (NTC) and the T. suis protein-coding gene. Transfected L. tarentolae cells were polyclonally selected and maintained as described in the manual.
2.14. Protein Purification. His 6 -tag fused, recombinant proteins secreted by transfected Leishmania cells were purified by liquid chromatography over His-Trap™ excel columns (GE Healthcare, Buckinghamshire, United Kingdom). Protein-containing fractions were pooled and dialyzed two times against PBS (4 h and overnight). Finally, protein concentrations were assessed using Pierce™ BCA Protein Assay Kit (ThermoFisher Scientific, Rockford, USA). Identity of  [39] and processed using XDSAPP [40]. Relevant processing statistics are shown in Table 2. The structure was solved by molecular replacement using the structure of human chitotriosidase (CHIT1) as a search model (PDB-Id 5HBF, [41]). After several cycles of manual rebuilding using COOT [42] and refinement using REFMAC5 [43], refinement converged at R factors of 19 and 23% for the working R and the free R, respectively ( Table 3). The refined structure features good refinement statistics and excellent geometric parameters. The refined coordinates and the associated structure factor amplitudes were deposited in the PDB using the accession code 6G9C.

Structure-Based Sequence Alignment and Surface
Electrostatics. To obtain an overview of structural similarities and differences between Ts-Chit and host chitinases, the topology and secondary structure elements of Ts-Chit were compared to six mouse chitinases and chitinase-like proteins by means of a structure-based amino acid sequence alignment (see Supplementary Information S2). Secondary structure elements were predicted with PSIPRED [44], and a structure-based amino acid sequence alignment was constructed using SBAL [45]. In order to assess whether Ts-Chit possesses any features that might serve as a potential molecular mimicry of host chitinases when acting as an antigen, we undertook a comparison of surface features of Ts-Chit with mouse chitinases. In general, this approach is limited by the availability of only one experimental 3D structure of mouse chitinases. Using the amino acid sequences of three mouse chitinases (M. musculus AMCase, Chit1 isoform 1, and Ym1), known 3D structures or close structural homologues of these proteins were identified in the PDB using pGenThreader [46], revealing mouse AMCase as the only mouse protein suitable for comparison in this context.

T. suis L1 Stage-Specific Excretory-Secretory Protein
KFD48490.1 Affects Allergic Airway Inflammation. We previously showed that T. suis excretory/secretory proteins (ES proteins) collected from L1 hatched in vitro reduced clinical signs of murine allergic airway disease [34]. To identify proteins responsible for this effect, we now investigated the protein composition of L1 ES proteins and compared it to L2, L3, and L4 larval stages of T. suis-released products. For stage-specific expression patterns, parasites were isolated from pigs infected with 8000 TSO at 10, 18, and 28 days postinfection (resulting in L2, L3, and L4 larvae, respectively) and cultivated to collect conditioned media for mass spectrometry. Alternatively, eggs were hatched in vitro to generate L1 larvae and conditioned media, as previously described [34]. Comparative proteomic analysis of T. suis ES proteins (Figure 1(a) and Supplementary Table S1) revealed some overlap between first stage (in vitro hatched) L1 larvae and L2 larvae (10 day larvae), but no overlap of L1 ES proteins with later stages of larval development (L3 ES from 18 day larvae and L4 ES from 28 day larvae). Four L1-specific proteins and two L1/L2-specific proteins with predicted signal sequences and a lack of transmembrane domains ( Table 2) were recombinantly expressed. Since glycosylation can be crucial for the immunomodulatory effects of secreted helminth proteins, we used the eukaryotic expression system LEXSY, based on the protozoan L. tarentolae (Figure 1(b)). Notably, selected T. suis L1 proteins were distinct in size (ranging from 13 to 56 kDa, Figure 1(c)), predicted glycosylation sites and homology-based annotation ( Table 2).
We initially screened for immunomodulatory effects of the six recombinant T. suis L1 proteins using the OVA-(ovalbumin-) induced allergic airway hyperreactivity model in female BALB/c mice. Mice were treated with recombinant T. suis proteins during sensitization with the allergen OVA on days 0, 7, and 14 ( Figure 1(d)). The numbers of total BAL infiltrates and BAL eosinophils were detected 2 days after the 2 nd intranasal OVA challenge at day 31 ( Figure 1(d)) and analyzed in parallel to control mice lacking OVA sensitization, but receiving OVA-challenged mice (PBS) and untreated allergic mice (OVA). Analysis of total cell numbers and cellular composition of the BAL fluid found that KFD48490.1 (homologous to T. trichiura acidic mammalian chitinase) and KFD45500.1 (homologous to T. trichiura venom allergen 5) reduced the total numbers of cellular BAL fluid infiltrates, but only KFD48490.1-treated mice showed a significant reduction of eosinophils infiltrating the lungs in comparison to untreated allergic (OVA) mice (Figures 1(e) and 1(f)).
3.2. Immunoregulatory KFD48490.1 Is an Active Chitinase of T. suis L1 Larvae. Based on amino acid sequence similarity, database research predicted KFD48490.1 was homologous to acidic mammalian chitinase (AMCase) of T. trichiura ( Table 2). The amino acid sequence of KFD48490.1 revealed the presence of the catalytic motive DxDxE (T. suis DLDWE, Figure 2(a)), typically observed for active chitinases, and a C-terminal chitin-binding domain with cysteine residues responsible for the chitin binding (Figure 2(a)). Alignment studies additionally proved high sequence similarities to other known helminth chitinases including a putative endochitinase from the pig infecting Ascaris suum and a glycosyl hydrolase from the human hookworm N. americanus (Figure 2(b)). Active chitinases cleave chitin from the end of a polymer chain (exochitinase) and/or hydrolyse small oligomers to generate N-acetylglucosamine monomers within the oligomer chain (endochitinase) [49]. To examine whether KFD48490.1 exerts true chitinase activity, we used two different substrates, 4-MU-(GlcNAc) 3 and 4-MU-(GlcNAc) 2 , allowing us to evaluate both endo-and exochitinase activity, respectively (Figure 2(c)). KFD48490.1 clearly presented both, endo-and exochitinase activity, whereas extensive, heat-induced proteolysis resulted in a loss of chitinase activity (Figure 2(c)).
With regard to the biology of nematodes, we explored the influence of low pH and high temperatures hypothesizing that T. suis chitinase will be active at low pH and elevated temperatures in the pig's intestine to support larval  [50,51]. Interestingly, KFD48490.1 remained enzymatically active over a wide range of pH 4-7 ( Figure 2(d)) and up to temperatures of 50°C (Figure 2(e)). Together, these data confirmed the functional annotation of KFD48490.1 as T. suis L1 true chitinase, and thus, the protein is referred to as Ts-Chit from hereon.     [4,31,36,52,53], the suppression of antigen-specific or unspecific CD4 + T cell proliferation [54], or induction of Foxp3 + regulatory T cells [19,55]. Hence, we investigated T. suis chitinase (Ts-Chit) activity on dendritic cell activation and T cell proliferation. Recombinant Ts-Chit did not interfere with upregulation of LPS-or CpG-induced activation markers on bone marrow-derived dendritic cells (BMDC) such as MHCII, CD86, or Ox40L (Figures 3(a) and 3(b)). While CpGinduced proinflammatory cytokine expression was not affected (Figure 3(c)), we observed reduced secretion of LPS-induced IL-12p40 and TNFαwhen BMDC were treated with Ts-Chit. We could also not detect induction of regulatory IL-10 in BMDC (Figure 3(c)). Similarly, TCRunspecific proliferation of CD4 + and CD8 + T cells was      (Figures 3(f) and 3(g)). Again, we did not observe significant effects on T cell polarization (Figure 3(g)). Although a strong, direct immunomodulatory activity of Ts-Chit was not established by the in vitro assays that we performed, we aimed to decipher what caused the in vivo effects of the nematode chitinase and went back to the mouse model of AHR.

T. suis Chitinase-(Ts-Chit-) Mediated Regulation of Airway Hyperreactivity Only Partially Depends on Protein
Integrity. To investigate the effects of Ts-Chit treatment on allergic airway disease, we analyzed airway resistance, expiration time, and BAL fluid profiles in more detail. In addition, we included a group of mice treated with

13
Journal of Immunology Research heat-inactivated, recombinant Ts-Chit to assess whether immunomodulatory effects were linked to the enzymatically active T. suis chitinase protein.
Treatment of animals with intact and active Ts-Chit significantly reduced the number of total cells (Figure 4(a)) and eosinophils (Figure 4(b)) present in BAL fluid 2 days after 2 nd OVA challenge. Differential cell counts of BAL fluid further revealed that neutrophil numbers were largely unaffected (Figure 4(c)). A trend towards an increase of alveolar macrophage cell numbers was observed in Ts-Chit compared to allergic (OVA) mice (Figure 4(d)). Flow cytometry of BAL cells confirmed the reduced frequency of eosinophils (CD45 + CD11b + GR1 low CD11c -SiglecF + ) in Ts-Chit-treated compared to untreated (OVA) allergic animals (Figures 4(e) and 4(f)) and also supported increased frequencies of alveolar macrophages, identified as CD11b low CD11c + cells among CD45 + cells (Figure 4(g)), as observed as a trend in differential cell counts. The respiratory responses resulting from Ts-Chit treatment were measured using noninvasive whole-body plethysmography 24 h after OVA challenge. Importantly, also, the nonsensitized control group (PBS) was intranasally challenged with OVA. Preventative administration of Ts-Chit caused restoration of expiration time to the level of PBS control mice at baseline (Figure 4(h)). A trend in recovery was also noticed for treating with heat-inactivated Ts-Chit (Figure 4(h)). Measuring airway resistance to increasing doses of methacholine (MCh) revealed that Ts-Chit treatment attenuated exacerbation of MCh-induced airway hyperreactivity, but treatment with inactivated Ts-Chit also had some effects (Figures 4(h)-4(j)). We next evaluated whether the reduced cellularity and improved lung function observed in Ts-Chit-treated animals were reflected in BAL cytokine levels. OVA sensitization and challenge caused a significant increase of the cytokines IL-4, IL-5, and IL-13 detected in BAL fluid; however, Ts-Chit treatment did not reduce but rather enhanced local Th2 cytokine production (Figure 4(k)). Of note, TNFα levels in BAL did not vary among groups (data not shown). Interestingly, Ts-Chit and heat-inactivated Ts-Chit alike accelerated IL-18 levels in BAL fluid (Figure 4(k)), a cytokine known to induce IL-4, IL-5, and IL-13 release by mast cells and basophils [56]. Thus, cellular infiltration and the respiratory response were improved in mice treated with Ts-Chit, but Th2 cytokine level in BAL was unchanged or elevated in comparison to untreated allergic mice (OVA). Phenotyping of lung inflammatory CD4 T cells revealed elevated frequencies of IL-13-producing and GATA3-expressing Th2 cells in mice receiving Ts-Chit or inactivated Ts-Chit (Figure 4(l)), supporting our findings on enhanced local Th2 responses in chitinase-treated mice independent from the functional integrity of the nematode chitinase.
To further delineate the direct effects of Ts-Chit treatment on lung inflammation of OVA-sensitized and OVAchallenged mice, we investigated lung tissue pathology and recruitment of alternatively activated macrophages (AAM). While histopathological findings remained overall similar in the lungs of untreated (OVA) and Ts-Chit-treated allergic animals ( Figure 5(a)), immunohistochemistry revealed increased numbers of interstitial RELMα + cells, a signature   marker for AAM that mediates lung vascularization and tissue repair [57,58] when mice were treated with Ts-Chit compared to OVA (Figures 5(b) and 5(c)). A similar trend was observed for inactivated Ts-Chit-treated animals. Since this was in contrast to our previous observation on Ts-ES L1-induced suppression of RELMα + cells [34] and given that the resistin-like molecule (RELM) α is expressed not only in macrophages but also in epithelial cells and tissueinfiltrating eosinophils, we used smaller groups of mice to define RELMα expression to a interstitial macrophage phenotype by flow cytometry. Lung tissue macrophages were analyzed in homogenates of lavaged lungs and defined as EpCAM -CD11c + CD64 + MHCII + SiglecF - (Figure 5(d)). While overall frequencies of tissue macrophages were not affected by Ts-Chit treatment ( Figure 5(e)), we again detected an increase in RELMα + macrophages but did not reach statistical significance ( Figure 5(f)). However, we found no indication for direct effects of Ts-Chit on RELMα + expression in macrophages when analyzing RELMα + mRNA levels in bone marrow-derived macrophages stimulated with recombinant Ts-Chit in vitro (data not shown). Contrary to the increase of RELMα + cells in the lung, RT-PCR of homogenized lung tissue of all groups of mice revealed downregulation of arginase-1 and MCP-1 mRNA when mice were treated with intact and also inactivated Ts-Chit compared to PBS (Figure 5(g)). Supporting reduced numbers of eosinophil infiltration upon Ts-Chit treatment, we detected downregulation of CCL11/eotaxin mRNA, a potent eosinophil chemoattractant that stimulates recruitment of eosinophils from the blood to sites of allergic inflammation ( Figure 5(e)). Together, these data illustrate that protein integrity of the Ts-Chit is only partially responsible for the treatment effects leading to attenuated airway hyperreactivity.

T. suis Chitinase Treatment Interferes with Murine
Chitinase in AHR. From our in vitro and AHR experiments, we concluded that a direct immunomodulatory effect of T. suis chitinase or its chitinase activity was very unlikely. However, considering the high sequence similarities to known chitinases and CLPs, we asked whether Ts-Chit treatment of allergic mice interfered with the effector functions of its murine counterpart, the acidic mammalian chitinase (AMCase). AMCase is secreted by macrophages and epithelial cells of the lung and gut and in the lungs constitutively expressed and secreted into the airway lumen. STAT6activating signals, such as IL-13, further induce AMCase expression, and elevated AMCase mRNA and protein levels are detected in BAL of OVA-induced asthmatic mice [59]. Experimentally, the administration of anti-AMCase sera was shown to reduce BAL and tissue eosinophilia and BAL chitinase activity [59]. We therefore examined BAL fluid of allergic mice for chitinase activity. And indeed, chitinase activity was found to be reduced in the BAL of allergic mice treated with intact and inactivated Ts-Chit compared to untreated (OVA) mice (Figure 6(a)). In line with that, we detected decreased AMCase transcript level (Chia1) mRNA transcripts in lung tissue snips of allergic Ts-Chit-treated compared to untreated (OVA) mice (Figure 6(b)). We therefore examined the implications of Ts-Chit treatment on the family of murine chitinases and chitinase-like proteins (CLP) that are highly implicated in pathology of Th2-
3.6. T. suis Chitinase Reveals High Structural Similarity to Murine Chitinase but Presents Dimeric Structure. To better understand structural differences between nematode and mammalian chitinases, we determined the crystal structure of the nematode chitinase protein by X-ray crystallography.
The final model analysis data collection and refinement statistics are summarized in Table 3. They indicate that the structure is of high resolution, that it is well refined to very good statistics, and hence that it is of high quality. The overall structure reveals a TIM-barrel or (βα)8-barrel motif, which means that 8 β-strands form the central barrel which is surrounded by 8 α-helices (Figures 7(a) and 7(c)). The active site with the sequence motif D 149 xD 151 xE 153 is depicted in Figure 7 A.2. The crystal structure furthermore revealed a C2-symmetric dimer of the protein, which is stabilized by an intermolecular disulfide bond formed by a cysteine residue at position 180 (Figures 7 A.1 and 7(b)). Such dimerization has not been described so far for human or murine chitinases, nor has the occurrence of a cysteine residue at position 180. In addition, the structural alignment with human AMCase (3FXY), human chitotriosidase (1GUV), human YKL-40 (1NWR), and murine Ym1 (1VF8) (Figure 7(c)) indicates highly similar structural features in the core regions (marked in red) and certain areas, mostly at the protein surface, where the structure differs between nematode and mammalian chitinases (highlighted in green/blue). A detailed structure-based sequence alignment of T. suis chitinase, mouse chitinases, and CLPs is given in Supplementary S2. Notably, the C-terminal region of Ts-Chit from amino acids 401 to 495 contains many threonine repeats and is referred to as unordered region. The T. suis chitinase dimerization was further examined by comparing reducing (+ β-mercaptoethanol) and nonreducing (-β-mercaptoethanol) conditions for SDS/PAGE loading. We indeed detected a second, higher band at around 75 kDa indicative for dimerization under nonreducing conditions (Figure 7(d)). Following the idea that T. suis interferes with murine chitinase activity during allergic airway hyperreactivity, we more specifically compared surface features of Ts-Chit and AMCase (PDB: 3FY1), the only acidic chitinase with known experimental 3D structure. To that effect, the surface electrostatics for mammalian AMCase and the Ts-Chit monomer were visualized and appraised. While investigating the monomer alone did not reveal any strikingly identical surface patches, looking at the dimerization region around α3/ α4-α3 ′ /α4 ′ (α3:~127-142; α4:~161-180) revealed similarities with an acidic surface patch of AMCase (Figure 8(a)).
In summary, this first crystallographic structure analysis of a parasitic nematode chitinase revealed Ts-Chit dimerization and the concomitant existence of surface patches absent in the monomeric protein. The surface electrostatics of these dimer-specific patches show a remarkable similarity between T. suis chitinase and murine AMCase. The structural und functional similarity of T. suis chitinase and murine AMCase could either mean that Ts-Chit is sensed similar to murine AMCase resulting in cumulative effects or in turn that Ts-Chit interferes with murine AMCase function during lung inflammation.

Discussion
An efficient strategy of parasitic nematodes to ensure survival, growth, and reproduction in immunocompetent hosts involves immunoregulation of the host immune response. Being equipped with excretory and secretory   [61], parasitic nematodes release several products (ES products) that shape their host immune response [1]. It is those yet unidentified ES immunomodulatory molecules that bear the therapeutic potential for targeting immune-mediated diseases.
Following the complex life cycles of parasitic nematodes, there is evidence for life cycle stage-specific expression and release of distinct sets of ES molecules needed to fulfill specific tasks [31,62,63]. We have previously reported that total ES proteins of the very early larval stage (L1) of the whipworm T. suis very efficiently ameliorate allergic lung disease in a model of OVA-induced AHR when applied during the sensitization phase [34]. Notably, in TSO therapy for indications such as ulcerative colitis, Crohn's disease, or various autoimmune diseases including diabetes and multiple sclerosis (MS), patients are repeatedly exposed to the early larval stages of T. suis owing to the fact that T. suis only transiently infects human intestines [23,64]. Patients receiving TSO therapy, however, seem to not equally benefit from the worm therapy [22,[26][27][28]. In this context, we observed a considerable degree of interindividual variability in the adaptive immune responses to this helminth treatment [29] suggesting that even how the anti-TSO response is formed depends on the environmental and inflammatory context of the individual treatment.
This led us to suggest a role for mediators being released very early during infection by the first larval stages, and we therefore focused on the identification of specific L1 ES immunomodulators of T. suis and their potential immunomodulatory mechanisms. We compared ES proteins collected from hatched L1 versus later larval stages (10, 18, and 28 day old) isolated from the intestines of infected pigs by using LC-MS/MS. Among the 33 proteins that were identified in the ES of in vitro-hatched T. suis L1, 8 proteins were also found in the ES of L2 larvae, but no overlap to later larval stages. We concentrated on proteins selectively expressed   [65][66][67]. Over the course of this study, the genome of the porcine whipworm T. suis published in 2014 [68] had been complemented with two slightly larger assemblies of male and female worms that in turn added on to the number of identified protein IDs. Screening six recombinantly expressed L1 ES proteins, eukaryotically produced in L. tarentolae, in a model of OVA-induced allergic airway hyperreactivity revealed that the application of T. suis KFD48490.1 markedly reduced inflammatory lung infiltrates, partly mimicking the effects of total T. suis L1 ES [34]. Our results further proved that KFD48490.1 is an enzymatically active chitinase of T. suis. The enzyme retained its high activity in the pH range from 4 to 6 and thus is relatively resistant to acidic pH similar to what has been documented for acidic mammalian chitinases [69,70].
Chitinases are glycosyl hydrolases (GH) with the ability to directly degrade chitin polymers to low molecular weight chitooligomers (reviewed in [71]). Based on amino acid sequence similarity, the T. suis chitinase belongs to GH family 18 characterized by an enzyme core of 8 β-strands forming a barrel that is surrounded by α-helices, as well as the conserved sequence DxDxE forming the active site. Chitinases have essential roles in the life cycle of many parasites, supported by the existence of multiple genes as well as tissue-and stage-specific expression patterns [72][73][74]. Chitinase activity in helminth biology is thought to be essential during embryonic development, larval molting, and degradation of the chitinous matrix [75,76], suggesting that chitinases might be attractive intervention targets [50].
In the context of allergic lung disease, however, chitinases play a key role in mediating the Th2-driven inflammatory responses commonly associated with asthma and have been investigated to indicate disease severity [59,77,78]. Mice express two enzymatically active chitinases, acidic mammalian chitinase (AMCase) and chitotriosidase (Chit), and a set of enzymatically inactive chitinase-like proteins (Ym1, Ym2, and BRP39). AMCase is secreted by macrophages and epithelial cells of the lung and gut. In the lungs, it is constitutively expressed and secreted into the airway lumen. STAT6-activating signals, such as IL-13, further induce AMCase expression, and elevated AMCase mRNA and protein levels are detected in BAL of OVA-induced asthmatic mice [59]. Even though the mechanism of action of most mammalian chitinases and CLPs is not fully understood, stimulation of alveolar macrophages and enhancing tissue inflammation are likely to be involved. Hartl and coworkers [79] who showed that AMCase physically interacts with epidermal growth factor receptor (EGFR) to induce the production of, e.g., MCP-1, CCL17, and IL-8, in lung epithelial cells also reported an autocrine and/or paracrine feedback mechanism for AMCase in protecting airway epithelial cells from Fas ligand-(FasL-) and growth factor withdrawal-induced apoptosis [79,80]. Therefore, it is not surprising that blocking AMCase activity by administration of anti-AMCase sera reduced BAL and tissue eosinophilia [59]. Similarly, in a gut inflammation model, it has been shown that the panchitinase inhibitor caffeine was able to dampen inflammation in a DSS-induced colitis model [81].

Journal of Immunology Research
We now demonstrate that treating mice with a wormderived chitinase from T. suis (Ts-Chit) during sensitization reduced BAL infiltrates and eosinophilia, increased numbers of RELMα + interstitial cells, and improved overall lung function. Finding increased RELMα + lung macrophages might reflect an increased capacity of Ts-Chit-treated animals to limit Th2-mediated inflammation and initiate tissue repair [57].
Disease amelioration was linked to enhanced local Th2 responses in lung tissues, and heat-inactivated Ts-Chit was able to partly phenocopy these effects in vivo, suggesting that the functional chitinase domain is not entirely responsible for the effects observed. Using different in vitro assays, we investigated potential immunomodulatory effects of Ts-Chit on DC and T cell activation but found no evidence for a direct effect on immune cells as shown in other studies [31,55]. Yet, we cannot rule out any direct cellular effects of Ts-Chit on mammalian cells.
Our in vivo results, however, suggest a mechanism related to the one suggested by Zhu and colleagues [59] that report on blocking AMCase activity using antiserum treatment to reduce AHR severity. Similar to that study, we show here that Ts-Chit treatment had no suppressive effects on Th2 inductive responses such IL-4 and IL-13 as well as IL-5 levels. Zhu and coworkers further demonstrated that anti-AMCase sera diminished the ability of IL-13 to stimulate eotaxin and monocyte-chemotactic protein 1 (MCP-1), reflected by our results following treatment with the worm chitinase. Besides anti-AMCase treatment, other approaches have been used to address AMCase activity, such as inhibition with small molecule [82] or RNA interference [83], and demonstrated suppressed eotaxin, MCP-1, and MIP-1ß levels when AMCase activity or expression was inhibited.
Sequence alignment demonstrates a relatively high degree of similarity between T. suis chitinase and AMCase, but also to CLPs such as YM1, Ym2, or BRP39. Given the high homology of T. suis and murine chitinases, both summative and interfering effects would be conceivable. Our in vivo observations on reduced chemokine expression and eosinophil infiltration, but nonsuppressed Th2 responses, rather points towards a scenario where treatment with the worm chitinase interferes with the host's own chitinase activity triggered upon lung inflammation. As a first indication, we observed decreased host chitinase activity in BAL and a decrease in lung tissue AMCase transcripts following treatment with the structurally highly similar worm chitinase. Whether these findings are a consequence of the overall reduced lung inflammation or result from chitinase protein interference still needs to be verified.
The X-ray crystal structure of Ts-Chit reported here confirmed the expected high structural similarity of the nematode chitinase with murine acidic mammalian chitinase. In addition, analysis of surface electrostatics of the Ts-Chit dimer suggests the existence of an acidic surface patch on the nematode protein that bears similarity to a surface feature on AMCase monomers. This might point to molecular mimicry mechanisms, a phenomenon that is triggered by a high degree of similarity of pathogen and host epitopes. Future studies need to investigate whether structural similarity between T. suis chitinase and murine chitinases or CLPs is potentially linked to a serological response limiting activity of host AMCase similar to the study of Zhu and colleagues that applied anti-AMCase sera to ameliorate lung inflammation [59].

Conclusion
In summary, we investigated L1 stage-specific, secreted proteins of T. suis and their capacity for immunomodulation of allergic lung disease. We identified an active chitinase of T. suis that, when applied during sensitization of an allergic response, reduced eosinophilia and lung chemokine responses. These findings add to our understanding of specific functions of early secreted T. suis products in helminth biology and when considered as therapeutics to create an anti-inflammatory environment. The structural similarity between the worm chitinase and its host equivalent, the absence of direct cellular effects, and the potential to interfere with murine chitinase activity suggest an alternative mechanism of Ts-Chit ameliorating OVA-induced, allergic lung disease that likely involves structural mimicry. Such a mechanism of immunomodulation could be one of those unrecognized strategies of mediating anti-inflammatory responses.